A5071382647- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Palliative Care and End-of-Life Issues
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer survivorship and care
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Glycosylation and Glycoproteins Research
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Nutrition and Health in Aging
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Breast Cancer Treatment Studies
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Cancer, Hypoxia, and Metabolism
Phramongkutklao Hospital
2012-2024
Phramongkutklao College of Medicine
2021
Siriraj Hospital
2020
Mayo Clinic in Arizona
2014-2017
Mahidol University
2017
PURPOSE Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor ( EGFR )–mutated advanced non–small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. PATIENTS AND METHODS Patients with -mutated NSCLC who progressed after osimertinib platinum-based chemotherapy were randomly assigned 1:1 to receive or amivantamab, both combined lazertinib. Coprimary...
A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).
Historical outcomes in anaplastic thyroid cancer (ATC) have been dismal. To determine whether an initial intensive multimodal therapy (MMT) is associated with improved ATC survival. MMT was offered to all patients newly diagnosed treated at the Mayo Clinic from 2003 through 2015; vs care palliative intent (PI) individualized considering clinical status and patient preferences. Outcomes were retrospectively analyzed by American Joint Committee on Cancer stage treatments compared cohort data...
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted December according to previously established standard methodology, produce Pan-Asian (PAGA) ESMO consensus guidelines management Asian mCRC. presented this manuscript represent opinions reached by a panel experts mCRC representing oncological societies China (CSCO), Indonesia (ISHMO),...
Background. Cancer anorexia-cachexia syndrome (CAS) is a significant comorbidity among all patients with cancer, increasing the mortality rate. Almost head and neck cancer experience this syndrome. CAS causes increased energy expenditure by systemic inflammation decreasing consumption due to anorexia. It leads skeleton muscle breakdown reduces quality of life. Nutritional interventions primary treatment are mainstays manage situation. However, vicious cycle persist, especially in where...
Colorectal cancer (CRC) is a major cause of mortality. Currently used CRC biomarkers provide insufficient sensitivity and specificity; therefore, novel are needed to improve the detection. Label-free quantitative proteomics were identify compare glycoproteins, enriched by wheat germ agglutinin, from plasma patients age-matched healthy controls. Among 189 identified levels 7 15 glycoproteins significantly altered in non-metastatic metastatic groups, respectively. Protein-protein interaction...
Abstract Background Palliative care for patients with advanced cancer improves suffering symptoms, and quality of life (QoL). However, routine implementation palliative by specialty consultation is still an unmet need among in-patients cancer. Our study aim to evaluate the effectiveness a team-based approach on QoLs readmission rate when compared practice medical oncologists. Methods This was prospective, Quasi-Experimental design. In-patients were non-randomly assigned receive service or...
We aim to investigate the effect of curcumin on preventing cancer anorexia-cachexia syndrome (CACS) via through mechanism inhibition NF-kB signal pathway. Outcome measurement for primary end point was improvement body tissue composition, and secondary points were weight mass index, hand grip muscle strengthening, safety.
PURPOSE Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the PROs atezolizumab bevacizumab. MATERIALS AND METHODS From September 2020 August 2021, 30 patients with who met inclusion criteria as were enrolled. Analysis was assessed progression-free survival, overall adverse events (AEs),...
Nephrotoxicity is a major dose-limiting toxicity among patients with cancer who were treated cisplatin. Although no standard approach available to prevent cisplatin-induced nephrotoxicity, administering intravenous isotonic saline recommended. Additionally, mannitol combined hydration has been evaluated, but none of them have established. Our study aimed determine the efficacy nephrotoxicity.This was phase II, randomized, placebo-controlled design. All solid cancers cisplatin (n = 48)...
Even in the immuno-oncology era, transcatheter arterial chemoembolisation (TACE) is most effective way to treat intermediate stage hepatocellular carcinoma (HCC). Postembolisation syndrome (PES) common side effect from TACE and there still no standard prevention guideline.To evaluate efficacy of single dose intravenous dexamethasone regimen prevent PES after among patients with HCC.This study enrolled HCC who had eligible indication for without macrovascular invasion/extrahepatic metastasis....
Introduction Cancer care monitoring should be adapted regarding COVID-19 pandemic preparedness plans. Lung Care application was a mobile program to monitor adverse events and report outcomes. This study is aimed invent new evaluating patient-reported outcome (PRO) for patients with non-small cell lung cancer (NSCLC) evaluate the validity of application, particularly during era. Methods The tested, Functional Assessment Therapy-Lung (FACT-L) questionnaires were contained in application-based...
e24051 Background: The CurChexia study, NCT04208334, is a phase IIa randomized control trial. study demonstrates the benefits of adding 4,000 mg curcumin to standard nutritional intervention. This addition helps increase muscle mass and delay decrease in other body composition parameters. However, clinicians require treatment that maintains or improves quality life (QoL) head neck cancer patients. In this report, we present QoL data. Methods: Patients participating were required complete...